Quadrivalent Influenza Standard Dose Vaccine
Quadrivalent Influenza Standard Dose Vaccine is a biological therapy with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
100.0%
3 of 3 finished
0.0%
0 ended early
1
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older
Clinical Trials (4)
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4